Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools

Patient Care spoke with renowned cardiologist Dr Mikhail Kosiborod and widely-recognized family physician Dr Neil Skolnik, about the expanded indications for sodium-glucose cotransporter-2 (SGLT2) inhibitors and how their availbility creates the perfect opportunity to broaden the scope of type 2 diabetes (T2D) management, with treatment goals that target a patient's full cardiometabolic profile, not elevated blood glucose alone.

In this final part of the conversation Kosiborod and Skolnik each highlight 3 thoughts for primary care clinicians to keep in mind that will help broaden their view of caring for their patients with T2D.

For more of the conversation with Drs Kosiborod and Skolnik, please see:

• SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
• Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik

Mikhail Kosiborod, MD, is professor of medicine, University of Missouri Kansas City, vice president, Research, Saint Luke’s Health System, executive director, Cardiometabolic Center Alliance, Director, Cardiometabolic Research and codirector, Haverty Cardiometabolic Center of Excellence, Saint Luke’s Mid America Heart Institute, Kansas City, MO.

Neil Skolnik, MD, is professor of family and community medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.